To develop best practices, tools, capacity and capability for an effective formulary management system for five public health care institutions in Singapore. METHODS: A survey was conducted among formulary committee members of the participating institutions as part of gap analysis. A cross-institution task force comprising decision makers, clinicians, pharmacists and health technology assessment (HTA) researchers from participating institutions was formed to recommend best practices for formulary submission, evidence review and synthesis, pharmacoeconomic evaluation and criteria for decision making. Endorsement from participating institutions' stakeholders was obtained before the implementation of this programme. RESULTS: The gap analysis highlighted three key areas for improvement: 1) methodologies for evidence review and synthesis, and pharmacoeconomic evaluation; 2) criteria for formulary decision making; and 3) capacity and capability building especially in pharmacoeconomics. A set of tools that facilitate evidence review and synthesis including guidelines for pharmacoeconomic evaluation was developed with reference to published literatures and international guidelines. Clinical need, safety, efficacy, cost-effectiveness, budget impact and opinion from subject matter experts were deemed as important decision-making criteria. A decision-making form incorporating these criteria was created to facilitate the consistency and transparency of the decision making process. Workshops focused on HTA were conducted to equip pharmacists supporting formulary management for participating institutions the knowledge and skills to appraise clinical and economic evidence. In addition, a team comprising personnel trained in pharmacoeconomics was set up to provide support to institutions pharmacists on the application of HTA via joint review on selected new drug applications. CONCLUSIONS: Support from participating institutions formulary committees and senior management are keys for the successful implementation of this programme. Moving forward, the challenge is to integrate the proposed changes into current practice.
OBJECTIVES:
To evaluate doctors' knowledge, attitude and practices on Malaysian CPG 2008 along with factors predicting guidelines adherence and hypertension control. METHODS: This was a co-relational study conducted at Hospital Pulau Pinang, Malaysia. A total of 26 doctors were enrolled. Doctors' knowledge and attitude on CPG (2008) were evaluated through a valid and reliable questionnaire. In order to evaluate doctors' actual prescribing practices, prescriptions written by 26 enrolled doctors to 650 established hypertensive outpatients (25 prescriptions per doctor) were noted on visit one. The noted prescriptions were classified either as compliant or noncompliant to CPG (2008) . Five hundred and twenty enrolled patients (20 patients per doctor) were followed for one more visit. Blood pressure noted on visit 2 was related to the prescription written on visit one. SPSS 16 was used for data analysis. RESULTS: Nineteen doctors (73.07%) had adequate knowledge of CPG (2008) . Doctors were highly positive towards CPG (2008) with mean attitude score of 23.15ϩ1.34 points on a 30 point scale. Statistically significant correlation (r s ϭ0.635, p-valueϽ0.001) was observed between doctors' knowledge and practice scores. The majority (67.1%) patients received guidelines compliant therapy. In multivariate analysis hypertension clinic (ORϭ0.398, p-valueϭ0.008) was the strong predictor of poor adherence with guidelines. On visit Two 51% patients were at goal BP. In multivariate analysis, Angiotensin converting enzyme inhibitors (ORϭ2.100, p-valueϭ0.001) and guidelines adherence (ORϭ1.745, p-valueϭ0.022) were the strong predictors of hypertension control, while renal disease (ORϭ0.283, p-valueϽ0.001), diabetes mellitus (ORϭ0.598, p-valueϭ0.025) and diabetic clinic (ORϭ0.384, p-valueϭ0.024) were the strong predictors of poor control of hypertension. CONCLUSIONS: An overall fair level of doctors' knowledge, adherence with guidelines and control of hypertension was observed. The gaps between what guidelines recommended and clinical practice was especially seen in the pharmacotherapy of uncomplicated hypertension and hypertension with diabetes mellitus and renal disease.
PHP105 GUIDELINE IMPLEMENTATION IN LONG TERM ASTHMA MANAGEMENT: AN AUDIT USING A MEDICATION ASSESSSMENT TOOL IN SELAYANG HOSPITAL
Shaharuddin S 1 , Che Hasan MH 1 , Hashim R 2 1 UiTM, Bandar Puncak Alam, Selangor, Malaysia, 2 CUCMS Main Campus, Cyberjaya, Selangor, Malaysia OBJECTIVES: To assess the current practice for the management of long term asthma in Malaysia and the prescribing pattern among asthmatic patients by using medication assessment tools (MAT). The MAT was developed according to guideline used by the physicians in Selayang Hospital. METHODS: The development and validation of asthma MAT had undergone a process that involved selection of guideline on long term asthma management in adults. The recommendations were focused on pharmacologic management. Updated version of GINA guidelines was used as GINA guidelines is known to be used in the management of long term asthmatic patients in Selayang Hospital. The MAT tool was then discussed and validated together with practising pharmacist. Pilot sampling was done and data was then collected from patient medical record in Selayang Hospital. These data were then assessed using Microsoft Access and Microsoft Excel. RESULTS: The result showed that level of adherence towards guidelines used was 86.3% for 73 asthmatic patients that were selected. If magnification was made, however, the reduction of current medication dose had not been made after the symptoms of asthma have been controlled and only 39.4% had their dose reduced according to the guideline. CONCLUSIONS: The adherence of guidelines seem to be high, however, improvement needs to be made in reducing the dose once patients' asthmatic symptoms have been resolved.
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DIFFUSION OF NON-GUIDELINE EXPERIENCE-BASED CHEMOTHERAPY CARE
Tien YY 1 , Brooks J 1 , Wright K 1 , Link B 2 , Chrischilles EA 1 1 University of Iowa, Iowa City, IA, USA, 2 University of Iowa, Iowa City, IA, USA Clinical guidelines recommend patients with Diffuse Large B-Cell Lymphoma (DL-BCL) receive anthracycline-based chemotherapy (ABC) treatment. During the 1990s, however, about one-third of elderly DLBCL patients did not receive chemotherapy, potentially due to intolerance of toxicities associated with ABC. With the addition of rituxmab in the late 1990s, it appears that physicians choose to use non-guideline rituximab plus non-ABC chemotherapy for patients with low toxicity tolerance. OBJECTIVES: This study assesses the diffusion of the use of nonguideline chemotherapy treatment for elderly DLBCL patients and examines the regional variation in diffusion. METHODS: A retrospective cohort consisting of 5839 Medicare beneficiaries diagnosed in 2000-2006 with primary DLBCL at age 66 or older treated with any chemotherapy was selected from the 2007 Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. Patients were excluded if physician information was not available (Nϭ55). Patient chemotherapy was categorized using Medicare claims within five months of diagnosis. Physicians (Nϭ3,072) were included if they prescribed any chemotherapy to patients during the initial treatment period. Descriptive analyses were used to characterize variation in chemotherapy treatment across the SEER registry regions. RESULTS: Physicians prescribed ABC chemotherapy to on average 81.2% of received chemotherapy patients. A totla of 19.8% of physicians, however, prescribed rituximab plus non-ABC chemotherapy to at least one patient. The percentage of physicians whom used rituximab plus non-ABC chemotherapy increased from 1.4% in 2000 to 16.1% in 2006. Louisiana, Connecticut, and Seattle were the top three SEER regions where over 23% of the physicians prescribed this alternative chemotherapy. In Hawaii, New Mexico, and Iowa SEER regions less that 14% of physician used this alternative chemotherapy. CONCLUSIONS: The percentage of physicians having adopted rituximab plus non-ABC chemotherapy as the alternative treatment increased over the years. Physicians' adoption of non-guideline treatment varies across regions.
PHP107
OBSERVATIONS OF HEPATOCELLULAR CARCINOMA (HCC) MANAGEMENT PATTERNS FROM THE GLOBAL HCC BRIDGE STUDY: AN INTERIM ANALYSIS OF HCC BURDEN OF ILLNESS IN THE ASIA-PACIFIC (AP) COHORT
OBJECTIVES: HCC has a substantial disease burden worldwide, especially in AP. The global HCC BRIDGE study is the first global, large-scale, observational study to document real-world treatment pattern and outcomes of HCC patients from diagnosis to death. METHODS: This longitudinal cohort study includes HCC patients newly diagnosed between January 2005 and June 2011 and treated at major medical centers, with data collected retrospectively and prospectively as recorded in patient charts. RESULTS: In the first interim analysis (July 2011), 8909 patients (mean age, 54 years; 83% male) were enrolled in AP (China, nϭ6295; Taiwan, nϭ1183; Korea, nϭ1136; Japan, nϭ295). The predominant risk factor was HBV in China (80%), Taiwan (67%), and Korea (77%), and HCV in Japan (69%). The predominant BCLC stage at diagnosis was stage C in China (56%) and Korea (51%) and stage A in Taiwan (55%) and Japan (47%). Variations were noted between China, Taiwan, Korea, and Japan in first-recorded treatment with resection/transplant (31%, 51%, 23%, 14%), TACE (53%, 27%, 55%, 24%), other locoregional therapy (9%, 18%, 8%, 52%), and systemic therapy (2%, 3%, 11%, 13%). There also were variations in treatment ever used with resection/transplant (34%, 53%, 29%, 16%), TACE (61%, 37%, 65%, 28%), other locoregional therapy (17%, 30%, 17%, 64%), and systemic therapy (5%, 9%, 30%, 19%). Recorded treatment by line of therapy, BCLC and mUICC stage, and country will be presented from the second interim analysis, which will include ϳ17,000 patients. Actual practice and expected practice according to guidelines will be evaluated, including how access issues may affect treatment availability. CONCLUSIONS: The global HCC BRIDGE study, which is the largest study of its kind (in approximately 19,000 patients), provides valuable insights into global HCC disease characteristics and patient management. Although AP has the highest HCC burden, practice approaches differ across the region.
PHP108
PATTERN OF ANTIBIOTICS USAGE IN MALAYSIAN HAJJ PILGRIM
them had upper respiratory infection due to congested and dusty environment. On previous observation may of hajj pilgrims were given antibiotic for their URTIs. Most of antibiotics prescribed to pilgrims were based on prescribers judgments.The study aims to determine the prevalence severity and the pattern of antibiotic usage. METHODS: This cross sectional study was conducted from December 2007 to January 2008. Validated self administered questionnaire forms were distributed to about 3,000 Malaysian Hajj Pilgrims in Makkah of Saudi Arabia. The severity of URTIs was based on the patient's perception and the number of symptoms. RESULTS: Majority, 87.1% of 2194 pilgrims reported had URTIs, 12.4%, (41.6%) and (46.0%) of pilgrims were categorised severe, moderate, and mild respectively. Antibiotics were prescribed to 58.8% pilgrims, the pattern of antibiotic used was associated with severity (p ϭ 0.001) and the number of symptoms(pϭ 0.001)and 55.1% of them had fever. Many of them(68.8%), take one course of antibiotic, while 28.5 % and 8.0% received two and three causes. CONCLUSIONS: A high prevalence of URTIs was found among Malaysian Hajj Pilgrims. Most of the pilgrims with moderate to severe and had fever received antibiotics. About one third of them, however, were not get benefit from first course of antibiotics. Proper antibiotic guideline that supported by microbiological studies are proposed to justify the use of antibiotics for hajj pilgrims.
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EVALUATION OF THE USE OF SEDATION FOR ADULTS USING MECHANICAL VENTILATORS IN A HOSPITAL IN TAIWAN
Chung MF 1 , Liu SC 2 , Kuo LN 1 , Chen HY 1 , Cheng KJ 1 1 Taipei, Wenshan Dist., Taiwan, 2 Taipei Medical University, Taipei, Xinyi Dist., Taiwan OBJECTIVES: To evaluate the use of sedatives in critically ill adult patients with endotracheal tube (ETT) and mechanical ventilator (MV) in a hospital in Taiwan.
Wan
METHODS:
We conducted the study retrospectively by reviewing medical records. All patients with ICD-9, 96.71, 96.72, 96.04, from Oct 2008 to Feb 2009 were included. Patients were excluded if they were pediatric patients, without complete records, using MV after discharged, in regular wards, or using MV less than 24 hours. The primary end point is the duration of mechanical ventilation. The secondary end points were length of ICU stay, hospital stay and events of tracheostomy, reintubation, self-extubation. Chi square and t-test were performed for dichotomous and continuous variables respectively. SPSS (Version 13.0) was used. The data were log transformed to address the non-normal distribution. RESULTS: We collected 50 events of insertion of endotracheal tube with mechanical ventilator (ETTϩMV) in using sedatives group and 163 in not using group. The duration of mechanical ventilation was not significantly difference between two groups. (pϭ 0.582) The using sedatives group had longer ICU (pϭ 0.04) and hospital length of stay (pϭ 0.001). There were much more patients were physically restricted in the using sedatives group (84% vs. 56%). The usages of sedatives were 50% of midazolam and 54% of propofol. The mean treatment duration among patients receiving midazolam was 4.6 days and 2.2 days among patients with propofol. This longer duration of length of stays were possibly related to the usage of midazolam and the prescribing habits of physicians. CONCLUSIONS: We found the physician preference by using physical restriction as first line and sedatives as second line did not benefit the critically ill patients. We will implement a sedation guideline to tailor the needs of our facility for optimal the patient care.
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REAL-WORLD DIAGNOSIS AND TREATMENT PATTERNS OF IRON DEFICIENCY ANEMIA IN CHINA
Liu B 1 , Hao J 2 , Li Z 3 , Nie X 4 , Tang M 1 , Gao Y 3 , Yang H 1 , Hu S 5 1 School of Public Health, Fudan University, Shanghai, China, 2 Vifor Pharma Ltd., Glattbrugg, Switzerland, 3 Shanghai Centennial Scientific Co., Ltd., Shanghai, China, 4 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA, 5 Shanghai Health Development Research Center, Shanghai, China OBJECTIVES: To investigate the real-world diagnosis and treatment patterns of iron deficiency anemia (IDA) in China. METHODS: Literature review, Key Opinion Leaders survey, and patient case review were conducted. The review was based on China Academic Journals Full-text Database (2006) (2007) (2008) (2009) (2010) . A total of 163 publications were targeted by searching in terms of IDA diagnosis and treatment. A total of 44 senior physicians specialized in nephrology, hematology and obstetrics/gynecology were selected from tertiary hospitals in Beijing, Shanghai, Guangzhou, Shenyang and Chengdu, who were requested to complete a questionnaire in two weeks. The structured questionnaire included IDA awareness, diagnosis, treatment and related drivers and restrictions. Information on Lab tests and treatments were collected from 91 patient cases. Descriptive analysis was performed. The results of KOL survey and patient case review were consistent, indicating the validity of the results. RESULTS: IDA was most likely found in patients in nephrology and obstetrics/gynecology, and in patients with chronic kidney disease on hemodialysis. Seventy-five percent of nephrologists, 58% of hematologists, and 25% of obstetricians/gynecologists reported the existence of hospital-wide guidelines for IDA diagnosis and treatment, respectively. Lab tests and cut-off for IDA diagnosis varied across different specialties and different physicians in the same specialty. Intravenous (IV) iron was more effective and caused less side effects than oral iron. IV iron sucrose increased hemoglobin level faster and greater than intramuscular iron dextran. Nephrologists usually prescribed IV iron as the first line, while hematologists and obstetricians/gynecologists preferred oral iron. Price was not the most influential driver for using IV iron. Fifty-seven percent of KOLs, however, reported the restrictions of IV iron use due to cost. CONCLUSIONS: Guideline-based diagnosis and treatment for IDA needs to be strengthened in China. Real-world prescription of IV iron for IDA varied across specialties and may be restricted due to cost despite its better effectiveness.
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DEVELOPMENT OF NATIONAL MEDICINE BRAND SUBSTITUTION GUIDELINES AND PILOT ASSESSMENT OF ITS ADOPTABILITY AMONG COMMUNITY PHARMACIST AND GENERAL PRACTITIONERS IN THE STATE OF PENANG, MALAYSIA
Hassali MA 1 , Shafie AA 1 , Saleem F 1 , Atif M 2 , Masood I 3 , Chua GN 3 , Haq N 1 1 Universiti Sains Malaysia, Penang, Malaysia, 2 Universiti Sains Malaysia, Penang, P.Pinang, Malaysia, 3 Universiti Sains Malaysia, Penang, P. Penang, Malaysia OBJECTIVES: To develop national medicine brand substitution guidelines and assessment of its adoptability among community pharmacist and general practitioners in Malaysia. METHODS: A cross sectional postal survey was conducted with a sample of 100 community pharmacists and 100 general practitioners selected systematically in the state of Penang, Malaysia. A pre validated questionnaire was used for data collection. Frequencies and percentages were used to elaborate the data. SPSS v. 16 was used for data analysis. RESULTS: From a total of 200 questionnaires mailed, the response rate was 16% (nϭ16) for general practitioners and 36% (nϭ36) for community pharmacist. Majority of the respondents (nϭ53, 85.4%) disagreed that generic medicines lead to more side effect as compared to innovator brands. However, 59.6% (nϭ37) reported that Innovator brands are more effective than generic medicines. Moreover, (nϭ33, 53.2%) agreed that generics medicine are not bioequivalent to the innovator brands. Majority (nϭ40, 64.5%) stated that generic medicines should be available in same dosage form and strength as innovator brand medicines. Almost all respondents (nϭ52, 83.8%) demanded that dispensed medicines should be labelled with the generic (INN) name of the medicine with or without the brand name. While comparing with general physicians (nϭ13, 81.3%), community pharmacists (nϭ33, 91.7%) were in high favor that a written national generic brand substitution guideline is needed in Malaysia. In addition, all of the respondents strongly agreed to the statement that thorough counselling should be provided to the patients if their medicine is changed from innovator brand to generic in order to avoid confusion. CONCLUSIONS: Majority of general practitioners and community pharmacists in Penang agreed to the contents of the draft national medicine brand substitution guideline. This is a good indicator that the contents can actually be the foundation of an actual national medicine brand substitution guideline.
HEALTH CARE USE & POLICY STUDIES -Quality Of Care
PHP112 USAGE OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) BY DIABETES THERAPY TYPE IN LARGER CITIES IN CHINA
Mast O 1 , Tan A 2 , Zweyer S 1 , Perridy D 2 1 Roche, Mannheim, Germany, 2 Cegedim Strategic Data, Shanghai, China OBJECTIVES: SMBG is one of the core components of diabetes therapy. It supports a safe and effective drug therapy and provides additional feedback on how diet and lifestyle impact blood glucose levels. In 2011 a Chinese guideline on SMBG was published. SMBG, in contrast to most diabetes drugs, is not reimbursed. This study aims to assess the level of SMBG usage in patients on different diabetes therapies. METHODS: 1 st half year 2011 data (10,418 cases) from the CSD PDS Diabetes survey were used for this explorative analysis. PDS Diabetes is a syndicated research with a fixed representative panel of endocrinologists and cardiologists from 13 large Chinese cities. Patient cases are documented in a standardized format. SMBG usage was analyzed by therapy-subgroups: oral diabetes therapy only (OAD 54%), basal supported oral therapy (BOT 18%), conventional insulin therapy (CT 20%), intensive insulin therapy (IIT 6%) and OTHERS (2% -not reported). RESULTS: Ninety-five percent were patients with type 2 diabetes. A total of 5288 patients (50.8%) had a meter for home-testing. Shares of testers by therapies (OAD / BOT / CT / IIT) were 34.7%, 60.1%, 53.4% and 48.4%. Average weekly test frequencies were 2.8, 3.3, 3.0 and 4.0 respectively. In the IIT group 1% tested at least 3 times a day. HbA1c levels were by 0.2%, 0.5%, 0.4% and 1.2% lower in SMBG users. CONCLUSIONS: High share of patients don't have a meter to perform SMBG at home. For testers with BOT, CT and IIT test-frequencies remained clearly below the Chinese guideline recommending 10, 10 and 21 test per week respectively. For IIT (SMBG is needed to support insulin dose adjustments) only 1% tested at the guideline-recommende frequency. In IIT patients differences in HbA1 were largest between testers and non-testers. Further research is needed to clarify if e. g. education or reimbursement could potentially resolve these shortfalls.
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UTILIZATION OF FPG, HBA1C AND SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN COMMUNITY HEALTH CENTERS IN THE SHANGHAI AREA
Mast O 1 , Tan A 2 1 Roche, Mannheim, Germany, 2 Cegedim Strategic Data, Shanghai, China OBJECTIVES: Utilization of fasting plasma glucose (FPG), HbA1c and SMBG are considered core components of diabetes therapy. They support a safe and effective drug therapy and they provide feedback on the quality of glycemic control. In 2011 a Chinese guideline on SMBG was published. SMBG, in contrast to most diabetes drugs, is not reimbursed in China. This study aims to assess the level of SMBG usage with patients on different diabetes therapies in community health centers (primary care). METHODS: In 2012 a survey was conducted in community health centers in 6 districts of Shanghai. 935 random diabetes cases were documented in a standardized format. Subsequent explorative analysis were performed. SMBG usage was analyzed by therapy-subgroups: oral diabetes therapy only (OAD 84%), any therapy involving insulin (INSULIN 14%) and OTHERS (2%). RESULTS: 99% were patients with type 2 diabetes. FPG levels were available for 86% and 89% in OAD/ INSULIN respectively, HbA1c levels were available for 32.0% and 19.4% respectively. For 124 patients (13.3%) SMBG usage was reported, for 111 of them actual test A627
